Study Details

Back to Search Results

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02057380

Astellas Study ID

The unique identification code given by the study sponsor.

7487-CL-0209

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2013-004076-34

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Apr 2014 - Dec 2016

Masking

None (Open Label)

Enrollment number

13

A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site TH66002

Songkhla, Thailand, 90110

Site SG65002

Singapore, Singapore, 308433

Site US10001

Oklahoma City, United States, 73104

Site US10002

Baltimore, United States, 21287

Site US10004

La Jolla, United States, 92093-0987

Site TH66003

Khon Kaen, Thailand, 40002

Site US10008

Ann Arbor, United States, 48109

Site DE49001

Wuerzburg, Germany, 97080

Site US10006

Tampa, United States, 33612

Site DE49002

Berlin, Germany, 10117

Site PL48001

Szczecin, Poland, 70-891

Site BR55005

Porto Alegre, Brazil, 90610-000

Site CZ42001

Ostrava-Poruba, Czech Republic, 70852

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo